Salesforce CRM Analytics and Sales/Service Architect
About the job
- A bachelor's degree in Computer Science, Engineering, Information Systems, or a related field is required.
- At least 8 years of Salesforce platform experience is required.
- At least 4 years of hands-on Salesforce CRM Analytics or Einstein Analytics experience is required.
- Proven experience designing and implementing complex enterprise CRM Analytics dashboards and reporting solutions is required.
- Strong expertise in Salesforce Sales Cloud, Salesforce Service Cloud, CRM Analytics or Einstein Analytics, dashboard and KPI design, and enterprise data modeling is required.
- Experience with recipes, dataflows, SAQL, dashboard bindings, advanced lens development, and dataset optimization is required.
- Strong understanding of sales operations and customer support processes is required.
- Experience integrating Salesforce analytics with ERP, customer support, and enterprise systems is required.
- Knowledge of Salesforce Flow, APIs and integration patterns, and ETL and data transformation concepts is required.
- Experience working within Agile delivery environments is required.
- Lead the architecture, design, and implementation of Salesforce solutions across Sales Cloud, Service Cloud, and CRM Analytics.
- Design scalable enterprise reporting and analytics solutions using Salesforce CRM Analytics or Einstein Analytics.
- Partner with business stakeholders across sales, customer support, operations, customer success, and executive leadership teams to gather reporting and analytics requirements.
- Architect and implement complex CRM Analytics dashboards, datasets, lenses, recipes, and dataflows.
- Design KPI-driven executive dashboards for sales performance, forecasting, customer support operations, field service metrics, customer success, operational efficiency, and executive business reviews.
- Develop scalable data integration and transformation strategies across Salesforce and enterprise applications.
- Define best practices for analytics governance, security, data quality, and performance optimization.
- Design and implement Salesforce platform solutions leveraging Sales Cloud, Service Cloud, CRM Analytics or Einstein Analytics, and Data Cloud integrations.
- Collaborate with technical teams on integrations, APIs, ETL processes, and enterprise data architecture.
- Lead workshops, architecture reviews, roadmap planning, and stakeholder presentations.
- Provide hands-on leadership in dashboard development, analytics optimization, and Salesforce platform configuration.
- Mentor developers, analysts, and administrators on analytics and Salesforce best practices.
- Support release management, DevOps processes, and Agile delivery execution.
- Salesforce certifications such as Salesforce Certified Administrator, Salesforce Platform App Builder, Salesforce CRM Analytics and Einstein Discovery Consultant, Sales Cloud Consultant, Service Cloud Consultant, or Application Architect.
- Experience with Salesforce Data Cloud, Einstein Discovery, AI-driven analytics and predictive insights, Tableau integration, and Snowflake or enterprise data warehouse platforms.
- Experience in medical device, healthcare, or regulated industries.
- Experience building executive-level operational dashboards for large enterprises.
About the company
Intuitive Surgical makes da Vinci robots that let surgeons operate through a few small incisions, and Ion, a robot that reaches deep into the lungs to take tissue samples. In 2000, da Vinci became the first robotic system cleared by the FDA for general laparoscopic surgery, meaning keyhole operations in the abdomen. A surgeon sits at a nearby console and steers robotic arms holding a 3D camera and wristed instruments, which turn hand movements into smaller, steadier motions. Hospitals buy or lease the robots, then keep paying for the instruments used in each operation and for service. Intuitive was founded in 1995 to commercialize robotic surgery research from SRI International and is based in Sunnyvale, California.
Company Size
10,001+
Company Stage
IPO
Headquarters
Sunnyvale, California
Founded
1995
Get referred to Intuitive Surgical
See people who can refer or advise you
Simplify's Take
What believers are saying
- Demand keeps compounding: da Vinci procedures grew 15% and revenue 19%, to $2.89 billion, in the June 2026 quarter.
- Room to grow: Intuitive listed 748 open roles in October 2026, including 191 in engineering and 312 in Sunnyvale.
- Repeat sales steady the business: instruments and service made 76% of revenue in the June 2026 quarter.
What critics are saying
- Stock grants have shrunk: shares fell 27% from January to October 2026, versus 9% for rival Medtronic.
- Device giants are moving in: the FDA cleared rival robots from Medtronic in December 2025 and J&J in July 2026.
- Instrument sales face a court fight: in August 2026, an appeals court revived a repair firm's monopoly suit against Intuitive.
What makes Intuitive Surgical unique
- Hospitals rent more than they buy: 254 of 468 da Vinci systems placed in the June 2026 quarter were leases.
- It runs without borrowing: Intuitive had no debt and $8.6 billion in cash and investments in June 2026.
- Its CEO is a 30-year insider: Dave Rosa, CEO since July 2025, joined as employee number nine in 1996.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Hybrid Work Options
Growth & Insights and Company News
6 month growth
0%1 year growth
0%2 year growth
0%Intuitive Surgical has lost nearly 30% year-to-date in 2026, making it one of healthcare's biggest losers. The stock fell over 40% by late July. Despite this decline, Wall Street remains bullish—24 of 32 analysts surveyed by S&P Global in September rated it a "buy" or "strong buy." The medical device maker faces several challenges. Growth is slowing whilst the stock trades at a forward price-to-earnings multiple over 33. Competition in China remains difficult, and the company now battles healthcare giants Johnson & Johnson, Medtronic, and Stryker in robotic surgical systems. The expiration of Affordable Care Act subsidies and rising GLP-1 drug usage have also impacted procedure volumes. However, the company's Asian revenue still jumped 20% year-over-year in Q2, suggesting these headwinds aren't insurmountable.
Investors seeking financial stability often look to companies with more cash than debt, as these businesses have greater flexibility for growth investments, buybacks, and dividends. Intuitive Surgical holds $5.22 billion in net cash. The robotic surgery pioneer achieved 20.7% annual revenue growth over the past two years, whilst its earnings per share increased 17.4% annually over five years. IonQ maintains $2.06 billion in net cash, representing 14.1% of its market capitalisation. The quantum computing company posted 181% annual revenue growth over two years and expects 163% growth next year. Accenture has $1.78 billion in net cash. The professional services firm employs approximately 774,000 people across more than 120 countries. Companies with strong balance sheets can navigate uncertain markets whilst pursuing expansion opportunities without the burden of significant debt obligations.
Thermo Fisher and Intuitive Surgical both delivered strong recent quarters, but their premium valuations rest on different foundations. Thermo Fisher's case depends on recovery in life sciences spending after the pandemic slowdown. The company's Life Sciences Solutions segment saw reported revenue climb 13% year-over-year, with organic revenue up 3%. The Analytical Instruments business returned to growth after nearly two years of weak demand, suggesting laboratory spending is normalising. Intuitive Surgical maintains its premium through business model strength. The company's non-GAAP gross profit margin reached 70.0%, whilst its non-GAAP operating margin expanded 330 basis points year-over-year to 42.1%. Recurring revenue streams constitute roughly 85% of total sales. Intuitive placed 468 da Vinci surgical units in fiscal Q2, marking 18% year-over-year growth, indicating continued hospital investment in robotic surgery platforms.
Abbott Laboratories reported strong fiscal Q2 2026 results, with sales rising 13% on a reported basis and 4.8% on a comparable basis, beating estimates and prompting the company to raise its annual profit forecast. The diagnostics segment was particularly strong, growing 42% to $3.09 billion, driven by its cancer diagnostics business following the Exact Sciences acquisition. Intuitive Surgical also exceeded expectations in Q2 2026, with revenue growing 19% to $2.89 billion and adjusted EPS of $2.80, beating forecasts by $0.30. The company placed 468 da Vinci units during the quarter, an 18% year-over-year increase, whilst maintaining a non-GAAP gross margin of 70.0%. The companies present contrasting investment cases: Abbott offers diversified healthcare portfolio resilience, whilst Intuitive Surgical relies on its robotic surgery ecosystem with recurring revenue comprising approximately 85% of total sales.
Intuitive, the global leader in minimally invasive care and pioneer of robotic-assisted surgery, has signed a lease agreement with Penang Development Corporation for a new manufacturing facility in Malaysia. The 316,000-square-foot site in Bandar Cassia Technology Park will produce surgical instruments and electromechanical devices for Intuitive's da Vinci surgical system. The facility is expected to begin operations in 2028 and create 1,200 highly skilled jobs by 2032. The investment reflects Intuitive's commitment to Asia Pacific, where its da Vinci systems have treated more than 2.5 million patients across 13 markets over two decades. The expansion aims to support growing demand for robotic-assisted surgery across the region and strengthen Penang's position as a MedTech manufacturing hub in Southeast Asia.